Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-2004 in adolescents with autism spectrum disorder and gastrointestinal symptoms
ACTRN12618001956291Phase 2Recruiting
- Sponsor
- Axial Therapeutics
- Start
- Apr 2019
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of AB-2004 in Autism Spectrum Disorder (ASD), sponsored by Axial Therapeutics. Primary endpoint: Safety and tolerability of AB-2004. Started Apr 2019; status: recruiting.
02
Drugs
AB-2004
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on ACTRN12618001956291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001956291.